Anne Kessinger
Overview
Explore the profile of Anne Kessinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ernani V, Jahan R, Smith L, Marr A, Kimbrough S, Kos M, et al.
Cancer Treat Res Commun
. 2019 Nov;
22:100162.
PMID: 31675535
Background: Relapsed/refractory small cell lung cancer (SCLC) has a poor prognosis, with no good options. We evaluated a novel combination of topotecan and doxorubicin, providing sequential topoisomerase I and II...
2.
Bhatt V, Dsouza S, Smith L, Cushman-Vokoun A, Noronha V, Verma V, et al.
J Glob Oncol
. 2017 Jul;
3(3):208-217.
PMID: 28717762
Introduction: Epidermal growth factor receptor () mutations in non-small-cell lung cancers (NSCLC) may be more common in patients with brain metastases. Previous studies, however, did not adjust for effects of...
3.
4.
Huerter M, Meza J, Copur M, Tolentino A, Marr A, Ketcham M, et al.
J Geriatr Oncol
. 2016 Aug;
8(1):18-22.
PMID: 27491498
Objective: Platinum-based doublet chemotherapy is the standard for most patients with advanced non-small cell lung cancer (NSCLC). Toxicity concerns limit chemotherapy for patients over 70years. Vinorelbine and paclitaxel are effective...
5.
Ganti A, Shostrom V, Alorabi M, Zhen W, Marr A, Trujillo K, et al.
Clin Lung Cancer
. 2016 Jan;
17(4):285-91.
PMID: 26725852
Background: The median age at diagnosis of lung cancer is 70 years. However, the evidence guiding the management of octogenarians and older patients with non-small-cell lung cancer (NSCLC), is based...
6.
Bhatt V, Akhtari M, Bociek R, Sanmann J, Yuan J, Dave B, et al.
J Natl Compr Canc Netw
. 2014 Jul;
12(7):963-8.
PMID: 24994916
Philadelphia chromosome-positive acute myeloid leukemia (Ph(+)-AML) has a poor response to anthracycline- and cytarabine-containing regimens, high relapse rate, and dismal prognosis. Although therapy with imatinib and allogeneic stem cell transplantation...
7.
Ganti A, Gonsalves W, Loberiza Jr F, Aldoss I, Batra R, Silberstein P, et al.
Am J Clin Oncol
. 2014 Feb;
39(2):142-6.
PMID: 24487419
Background: Optimal management of locally advanced non-small cell lung cancer (NSCLC) lacks consensus. A retrospective analysis of patient data entered in the Veterans Affairs Central Cancer Registry was conducted to...
8.
Ganti A, Subbiah S, Kessinger A, Gonsalves W, Silberstein P, Loberiza Jr F
Clin Lung Cancer
. 2013 Dec;
15(2):152-8.
PMID: 24361249
Background: Racial disparities in outcomes of non-small-cell lung cancer (NSCLC) patients in the United States are well documented. A retrospective analysis of patients in the Veterans Affairs Central Cancer Registry...
9.
Islam K, Shostrom V, Kessinger A, Ganti A
Lung Cancer
. 2013 Aug;
82(1):90-4.
PMID: 23910907
Introduction: Outcomes following surgery are better than following radiation therapy (RT), for stage I NSCLC. Whether this is due to selection of healthier patients for surgery is unclear. This study...
10.
Bhatt V, Kedia S, Kessinger A, Ganti A
J Clin Oncol
. 2013 Jul;
31(25):3162-4.
PMID: 23897953
No abstract available.